JP2003514025A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003514025A5 JP2003514025A5 JP2001537965A JP2001537965A JP2003514025A5 JP 2003514025 A5 JP2003514025 A5 JP 2003514025A5 JP 2001537965 A JP2001537965 A JP 2001537965A JP 2001537965 A JP2001537965 A JP 2001537965A JP 2003514025 A5 JP2003514025 A5 JP 2003514025A5
- Authority
- JP
- Japan
- Prior art keywords
- aplidine
- use according
- formulated
- infusion
- dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- UUSZLLQJYRSZIS-LXNNNBEUSA-N plitidepsin Chemical compound CN([C@H](CC(C)C)C(=O)N[C@@H]1C(=O)N[C@@H]([C@H](CC(=O)O[C@H](C(=O)[C@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N2CCC[C@H]2C(=O)N(C)[C@@H](CC=2C=CC(OC)=CC=2)C(=O)O[C@@H]1C)C(C)C)O)[C@@H](C)CC)C(=O)[C@@H]1CCCN1C(=O)C(C)=O UUSZLLQJYRSZIS-LXNNNBEUSA-N 0.000 description 16
- 229950008499 plitidepsin Drugs 0.000 description 16
- 108010049948 plitidepsin Proteins 0.000 description 16
- 238000001802 infusion Methods 0.000 description 14
- 238000001990 intravenous administration Methods 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- PHIQHXFUZVPYII-ZCFIWIBFSA-O (R)-carnitinium Chemical group C[N+](C)(C)C[C@H](O)CC(O)=O PHIQHXFUZVPYII-ZCFIWIBFSA-O 0.000 description 1
- 229960004203 carnitine Drugs 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000001012 protector Effects 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9927006.8 | 1999-11-15 | ||
| GBGB9927006.8A GB9927006D0 (en) | 1999-11-15 | 1999-11-15 | Aplidine treatment of cancers |
| GB0005701A GB0005701D0 (en) | 2000-03-09 | 2000-03-09 | Antitumor utility of aplidine |
| GB0005701.8 | 2000-03-09 | ||
| GB0007639.8 | 2000-03-29 | ||
| GB0007639A GB0007639D0 (en) | 2000-03-29 | 2000-03-29 | Antitumour and anti-angiogenic compound |
| GB0015496A GB0015496D0 (en) | 2000-06-23 | 2000-06-23 | Antitumour and anti-angiogenic compound |
| GB0015496.3 | 2000-06-23 | ||
| GB0025209.8 | 2000-10-13 | ||
| GB0025209A GB0025209D0 (en) | 2000-10-13 | 2000-10-13 | Treatment of cancers |
| PCT/GB2000/004349 WO2001035974A2 (en) | 1999-11-15 | 2000-11-15 | Aplidine treatment of cancers |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003514025A JP2003514025A (ja) | 2003-04-15 |
| JP2003514025A5 true JP2003514025A5 (enExample) | 2008-01-10 |
Family
ID=27515929
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001537965A Pending JP2003514025A (ja) | 1999-11-15 | 2000-11-15 | ガンのアプリジン治療 |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US20090298752A1 (enExample) |
| EP (1) | EP1229922B1 (enExample) |
| JP (1) | JP2003514025A (enExample) |
| KR (1) | KR100518986B1 (enExample) |
| CN (1) | CN1423564A (enExample) |
| AT (1) | ATE363910T1 (enExample) |
| AU (1) | AU780417B2 (enExample) |
| BG (1) | BG65381B1 (enExample) |
| BR (1) | BR0015811A (enExample) |
| CA (1) | CA2391502A1 (enExample) |
| CY (1) | CY1106825T1 (enExample) |
| CZ (1) | CZ302498B6 (enExample) |
| DE (1) | DE60035120T2 (enExample) |
| DK (1) | DK1229922T3 (enExample) |
| ES (1) | ES2288486T3 (enExample) |
| HK (1) | HK1045648B (enExample) |
| HU (1) | HUP0203906A2 (enExample) |
| IL (1) | IL149488A0 (enExample) |
| MX (1) | MXPA02004862A (enExample) |
| NO (1) | NO330719B1 (enExample) |
| NZ (1) | NZ518847A (enExample) |
| PL (1) | PL200922B1 (enExample) |
| PT (1) | PT1229922E (enExample) |
| RU (1) | RU2261104C2 (enExample) |
| SI (1) | SI1229922T1 (enExample) |
| SK (1) | SK287762B6 (enExample) |
| WO (1) | WO2001035974A2 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030148933A1 (en) | 1990-10-01 | 2003-08-07 | Pharma Mar S.A. | Derivatives of dehydrodidemnin B |
| GB9803448D0 (en) | 1998-02-18 | 1998-04-15 | Pharma Mar Sa | Pharmaceutical formulation |
| UA76718C2 (uk) | 2000-06-30 | 2006-09-15 | Фарма Мар, С.А. | Протипухлинні похідні аплідину |
| NZ525196A (en) | 2000-10-12 | 2004-09-24 | Pharma Mar S | Treatment of cancers by aplidine in conjunction with a myoprotector |
| KR20050038578A (ko) * | 2001-10-19 | 2005-04-27 | 파르마 마르, 에스.에이. | 항종양성 화합물의 암치료에 있어서의 향상된 용도 |
| DE60229414D1 (de) * | 2001-10-19 | 2008-11-27 | Pharma Mar Sa | Verwendung von aplidine in der behandlung von pankreaskrebs |
| KR20060002778A (ko) | 2003-03-12 | 2006-01-09 | 파르마 마르, 에스.에이. | 개선된 항종양 치료 |
| DK1603584T3 (da) | 2003-03-12 | 2009-01-05 | Dana Farber Cancer Inst Inc | Aplidine til behandling af multipelt myelom |
| DK2029155T3 (en) * | 2006-02-28 | 2016-08-01 | Pharma Mar Sa | IMPROVED treatment of multiple myeloma |
| ATE479432T1 (de) * | 2006-11-03 | 2010-09-15 | Nerviano Medical Sciences Srl | Verfahren zur verabreichung einer antitumoralen verbindung |
| RU2360712C1 (ru) * | 2007-10-02 | 2009-07-10 | Федеральное государственное учреждение "Ростовский научно-исследовательский онкологический институт Росмедтехнологий" | Способ лечения местно-распространенного неоперабельного рака прямой кишки |
| CA2703024A1 (en) * | 2007-10-19 | 2009-04-23 | Giuseppe Longo Sorbello | Improved antitumoral treatments |
| MX2010009697A (es) * | 2008-03-07 | 2010-09-30 | Pharm Mar S A | Tratamientos anticancerigenos mejorados. |
| CN103463020B (zh) * | 2013-09-23 | 2015-11-25 | 李淑兰 | Lycojaponicumin A在制备治疗肾癌药物中的应用 |
| JOP20190254A1 (ar) | 2017-04-27 | 2019-10-27 | Pharma Mar Sa | مركبات مضادة للأورام |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4342744A (en) * | 1979-07-19 | 1982-08-03 | Lever Brothers Company | Hair treatment products |
| EP0048149B1 (en) * | 1980-09-12 | 1983-11-30 | University of Illinois Foundation | Novel antibiotics, derivatives thereof, processes for their extraction, and compositions containing them |
| US4493796A (en) * | 1980-09-12 | 1985-01-15 | Board Of Trustees, Univ. Of Ill. | Didemnins A, B, C, and derivatives thereof, as antiviral agents |
| US4950649A (en) * | 1980-09-12 | 1990-08-21 | University Of Illinois | Didemnins and nordidemnins |
| IT1153974B (it) * | 1982-09-23 | 1987-01-21 | Erba Farmitalia | Composizioni farmacologiche a base di cisplatino e metodo per il loro ottenimento |
| DE3684868D1 (de) * | 1985-09-20 | 1992-05-21 | Cernitin Sa | Verwendung von pflanzenpollenextrakten zur herstellung von das wachstum von tumorzellen hemmenden pharmazeutischen praeparaten und verfahren zu ihrer herstellung. |
| US20030148933A1 (en) * | 1990-10-01 | 2003-08-07 | Pharma Mar S.A. | Derivatives of dehydrodidemnin B |
| GB8922026D0 (en) * | 1989-09-29 | 1989-11-15 | Pharma Mar Sa | Novel anti-viral and cytotoxic agent |
| US5580871A (en) * | 1992-11-20 | 1996-12-03 | The Dupont Merck Pharmaceutical Company | 4-Heteroaryl- 1,4-dihydropyridine compounds with calcium agonist and alpha1 -antagonist activity |
| FR2698543B1 (fr) * | 1992-12-02 | 1994-12-30 | Rhone Poulenc Rorer Sa | Nouvelles compositions à base de taxoides. |
| US5462726A (en) * | 1993-12-17 | 1995-10-31 | Bristol-Myers Squibb Company | Method of inhibiting side effects of solvents containing ricinoleic acid or castor oil or derivatives thereof employing a thromboxane A2 receptor antagonist and pharmaceutical compositions containing such solvents |
| WO1995017901A1 (en) * | 1993-12-29 | 1995-07-06 | Matrix Pharmaceutical, Inc. | Methods and compositions for the treatment of a host with a cellular proliferative disease |
| US5861439A (en) * | 1994-11-14 | 1999-01-19 | Alza Corporation | Method for enhanced electrotransport agent delivery |
| US6365597B1 (en) * | 1996-02-14 | 2002-04-02 | Aventis Pharmaceuticals Inc. | 4-aza steroids |
| EP0914116B1 (en) * | 1996-05-22 | 2000-10-11 | Protarga Inc. | Compositions comprising conjugates of cis-docosahexaenoic acid and taxotere |
| US5795909A (en) * | 1996-05-22 | 1998-08-18 | Neuromedica, Inc. | DHA-pharmaceutical agent conjugates of taxanes |
| US6156724A (en) * | 1996-06-07 | 2000-12-05 | Rinehart; Kenneth L. | Uses of didemnins as immunomodulating agents |
| US6034058A (en) * | 1997-04-15 | 2000-03-07 | Rinehart; Kenneth L. | Semi-synthetic alanyl dilemnin analogs |
| EP0981352B8 (en) * | 1997-05-07 | 2009-06-17 | Pharma Mar, S.A. | Use of aplidine for the treatment of cardiovascular diseases |
| US6245759B1 (en) * | 1999-03-11 | 2001-06-12 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| US20010021380A1 (en) * | 1999-04-19 | 2001-09-13 | Pluenneke John D. | Soluble tumor necrosis factor receptor treatment of medical disorders |
| US6890904B1 (en) * | 1999-05-25 | 2005-05-10 | Point Therapeutics, Inc. | Anti-tumor agents |
| RU2323000C2 (ru) * | 2000-04-07 | 2008-04-27 | Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания | Аналоги тамандарина и дидемнина и способы их получения и применения |
| US6509315B1 (en) * | 2000-04-07 | 2003-01-21 | The Trustees Of The University Of Pennsylvania | Didemnin analogs and fragments and methods of making and using them |
| UA76718C2 (uk) * | 2000-06-30 | 2006-09-15 | Фарма Мар, С.А. | Протипухлинні похідні аплідину |
| MXPA03002479A (es) * | 2000-10-05 | 2004-05-24 | Immunex Corp | Polipeptidos de nectina, polinucleotidos, metodos para elaborarlos y uso de los mismos. |
| NZ525196A (en) * | 2000-10-12 | 2004-09-24 | Pharma Mar S | Treatment of cancers by aplidine in conjunction with a myoprotector |
| AU2002224417A1 (en) * | 2000-10-18 | 2002-04-29 | Immunex Corporation | Methods for treating il-18 mediated disorders |
| US6610399B1 (en) * | 2000-11-17 | 2003-08-26 | Structural Technologies, Llc | Multi-layer, thermal protection and corrosion protection coating system for metallic tendons, especially for external post-tensioning systems |
| DE60229414D1 (de) * | 2001-10-19 | 2008-11-27 | Pharma Mar Sa | Verwendung von aplidine in der behandlung von pankreaskrebs |
| DK1603584T3 (da) * | 2003-03-12 | 2009-01-05 | Dana Farber Cancer Inst Inc | Aplidine til behandling af multipelt myelom |
| KR20060002778A (ko) * | 2003-03-12 | 2006-01-09 | 파르마 마르, 에스.에이. | 개선된 항종양 치료 |
| EP1613338A4 (en) * | 2003-03-21 | 2009-06-24 | Madeleine M Joullie | TAMANDARIN ANALOGUES, FRAGMENTS THEREOF AND METHODS OF MAKING AND USING THE SAME |
| CA2528669A1 (en) * | 2003-06-09 | 2005-01-20 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
| DK2029155T3 (en) * | 2006-02-28 | 2016-08-01 | Pharma Mar Sa | IMPROVED treatment of multiple myeloma |
| CA2703024A1 (en) * | 2007-10-19 | 2009-04-23 | Giuseppe Longo Sorbello | Improved antitumoral treatments |
-
2000
- 2000-11-15 WO PCT/GB2000/004349 patent/WO2001035974A2/en not_active Ceased
- 2000-11-15 KR KR10-2002-7006155A patent/KR100518986B1/ko not_active Expired - Fee Related
- 2000-11-15 PT PT00976137T patent/PT1229922E/pt unknown
- 2000-11-15 CA CA002391502A patent/CA2391502A1/en not_active Abandoned
- 2000-11-15 JP JP2001537965A patent/JP2003514025A/ja active Pending
- 2000-11-15 ES ES00976137T patent/ES2288486T3/es not_active Expired - Lifetime
- 2000-11-15 SI SI200030960T patent/SI1229922T1/sl unknown
- 2000-11-15 RU RU2002115864/14A patent/RU2261104C2/ru not_active IP Right Cessation
- 2000-11-15 MX MXPA02004862A patent/MXPA02004862A/es active IP Right Grant
- 2000-11-15 DE DE60035120T patent/DE60035120T2/de not_active Expired - Lifetime
- 2000-11-15 AU AU14023/01A patent/AU780417B2/en not_active Ceased
- 2000-11-15 AT AT00976137T patent/ATE363910T1/de active
- 2000-11-15 IL IL14948800A patent/IL149488A0/xx unknown
- 2000-11-15 HK HK02106981.6A patent/HK1045648B/en not_active IP Right Cessation
- 2000-11-15 HU HU0203906A patent/HUP0203906A2/hu unknown
- 2000-11-15 DK DK00976137T patent/DK1229922T3/da active
- 2000-11-15 SK SK659-2002A patent/SK287762B6/sk not_active IP Right Cessation
- 2000-11-15 BR BR0015811-9A patent/BR0015811A/pt not_active Application Discontinuation
- 2000-11-15 NZ NZ518847A patent/NZ518847A/en not_active IP Right Cessation
- 2000-11-15 EP EP00976137A patent/EP1229922B1/en not_active Expired - Lifetime
- 2000-11-15 CZ CZ20021697A patent/CZ302498B6/cs not_active IP Right Cessation
- 2000-11-15 PL PL355335A patent/PL200922B1/pl not_active IP Right Cessation
- 2000-11-15 CN CN00818404A patent/CN1423564A/zh active Pending
-
2002
- 2002-05-14 NO NO20022293A patent/NO330719B1/no not_active IP Right Cessation
- 2002-05-18 BG BG106714A patent/BG65381B1/bg unknown
-
2007
- 2007-08-30 CY CY20071101110T patent/CY1106825T1/el unknown
-
2008
- 2008-12-23 US US12/342,478 patent/US20090298752A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY124853A (en) | 4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives. | |
| JP2003514025A5 (enExample) | ||
| JP2001515712A5 (enExample) | ||
| JP2002528502A5 (enExample) | ||
| CA2066403A1 (en) | Transmucosal dosage form | |
| CA2389235A1 (en) | Controlled release hydrocodone formulations | |
| RU98111594A (ru) | Фармацевтические композиции, включающие флурбипрофен | |
| CZ176495A3 (en) | The use of riluzol for preparing a medicament suitable for treating parkinson's disease and parkinson's syndromes | |
| CA2503810A1 (en) | Therapeutic agent for fibromyalgia | |
| BG106171A (en) | Compositions and uses of et743 for treating cancer | |
| WO2000041504A3 (en) | Use of tertbutylhydroquinone for lowering blood cholesterol and/or blood triblycerides | |
| RU95101385A (ru) | Продукты, содержащие g-csf и tnf связующие протеина | |
| CA2143610A1 (en) | Use of norastemizole for the treatment of allergic disorders | |
| JP2004537500A5 (enExample) | ||
| JP2002523437A5 (enExample) | ||
| CA2401000A1 (en) | Method of treating and diagnosing sleep disordered breathing and means for carrying out the method | |
| JP2002522501A5 (enExample) | ||
| MY124465A (en) | Reduction of infarct volume using citicoline | |
| JP2002530353A5 (enExample) | ||
| WO2001012214A3 (en) | MYCOPHENOLATE MOFETIL IN ASSOCIATION WITH PEG-IFN-$g(a) | |
| JP2002540148A5 (enExample) | ||
| EP1561462A3 (en) | Anti arrhytmic composition and methods of treatment | |
| WO1990004977A3 (en) | Treatment of genital warts with a combination of liquid nitrogen and recombinant dna human alpha interferon | |
| CA2474430A1 (en) | A combination of a thrombolytic agent and levosimendan for the treatment of acute myocardial infarction | |
| WO2001054678A3 (en) | Combination therapy for cancer |